Valuation: Cosmo Pharmaceuticals S.p.A

Market Cap 1.06B 1.2B 994M 909M 1.7B 115B 1.71B 11.94B 4.63B 58.82B 4.52B 4.42B 191B P/E 2026 *
915x
P/E 2027 * 21.2x
Enterprise Value 1.03B 1.17B 967M 884M 1.65B 112B 1.66B 11.61B 4.5B 57.24B 4.4B 4.3B 186B EV / Sales 2026 *
9.68x
EV / Sales 2027 * 5.84x
Free-Float
40.52%
Yield 2026 *
3.46%
Yield 2027 * 3.67%

Last Transcript: Cosmo Pharmaceuticals S.p.A

Manager TitleAgeSince
Chief Executive Officer 52 23/05/2024
Director of Finance/CFO - 10/11/2024
Chief Tech/Sci/R&D Officer 53 31/12/2008
Director TitleAgeSince
Chairman 71 31/12/2013
Director/Board Member 71 31/03/2012
Director/Board Member 54 23/05/2024
Change 5-day change 1-year change 3-year change Capi.($)
-1.31%+1.05%+53.92%+108.18% 1,043B
-0.32%+0.18%+51.64%+67.08% 649B
-0.14%+0.77%+18.83%+71.05% 469B
-0.25%+0.19%+36.95%+45.54% 355B
+0.98%+2.91%+20.59%+27.14% 270B
-1.91%+2.42%+10.41%+11.04% 262B
-0.67%+8.07%+41.80%+52.41% 222B
-1.49%+1.89%+31.53%+101.08% 189B
-2.53%-7.47%-32.63%-60.41% 175B
Average -0.80%+2.20%+25.89%+47.01% 403.67B
Weighted average by Cap. -0.76%+2.19%+35.64%+65.01%

Financials

2026 *2027 *
Net sales 106M 121M 99.92M 91.35M 171M 11.6B 172M 1.2B 465M 5.91B 455M 445M 19.18B 176M 201M 165M 151M 283M 19.21B 285M 1.99B 770M 9.79B 753M 737M 31.75B
Net income 1.27M 1.45M 1.2M 1.1M 2.05M 139M 2.06M 14.39M 5.58M 70.92M 5.45M 5.33M 230M 49.6M 56.51M 46.63M 42.63M 79.66M 5.41B 80.25M 560M 217M 2.76B 212M 208M 8.95B
Net Debt -28.5M -32.47M -26.79M -24.49M -45.77M -3.11B -46.11M -322M -125M -1.59B -122M -119M -5.14B -28.81M -32.82M -27.08M -24.76M -46.26M -3.14B -46.6M -325M -126M -1.6B -123M -121M -5.2B
Logo Cosmo Pharmaceuticals S.p.A
Cosmo N.V. formerly known as COSMO Pharmaceuticals N.V. is an Ireland based pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases, dermatology, and healthtech. Its development pipeline includes Distal Ulcerative Colitis, Bile Acid Diarrhea, Solid Tumors, and AI Augmented Endoscopy. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, which is used for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which is used for the treatment of travelers’ diarrhea (TD); Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy, and Winlevi, which is used for the treatment of acne. It also develops medical devices to assist with clinical decision-making.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!